Literature DB >> 20973796

MicroRNAs in cancer: personalizing diagnosis and therapy.

S Patrick Nana-Sinkam1, Muller Fabbri, Carlo M Croce.   

Abstract

MicroRNAs (miRNAs) are 19-24nt noncoding RNAs that have been implicated in the pathogenesis of both solid and hematological malignancies. Frequently located in fragile chromosomal regions, miRNAs are essential to key biological functions, such as cellular differentiation, apoptosis, and growth. miRNAs may serve as either tumor suppressors or oncogenes. As a result, they have the potential to serve as both biomarkers and therapeutic agents in cancer. Based on our presentation at the recent Towards Personalized Cancer Medicine conference held in Barcelona, Spain, May 19-21, 2010, we provide an overview of the current knowledge of miRNA deregulation in solid and hematological malignancies and their application as biomarkers of disease.
© 2010 New York Academy of Sciences.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20973796     DOI: 10.1111/j.1749-6632.2010.05822.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  16 in total

1.  Plasma microRNA might as a potential biomarker for hepatocellular carcinoma and chronic liver disease screening.

Authors:  Li Jiang; Xue Li; Qi Cheng; Bin-Hao Zhang
Journal:  Tumour Biol       Date:  2015-04-17

2.  A selective screening platform reveals unique global expression patterns of microRNAs in a cohort of human soft-tissue sarcomas.

Authors:  Peter Y Yu; Mumtaz Y Balkhi; Katherine J Ladner; Hansjuerg Alder; Lianbo Yu; Xiaokui Mo; William G Kraybill; Denis C Guttridge; O Hans Iwenofu
Journal:  Lab Invest       Date:  2016-02-15       Impact factor: 5.662

3.  miR-141 as potential suppressor of β-catenin in breast cancer.

Authors:  Nairi Abedi; Samira Mohammadi-Yeganeh; Ameneh Koochaki; Fariba Karami; Mahdi Paryan
Journal:  Tumour Biol       Date:  2015-07-13

4.  Regulation of miR106b cluster through the RB pathway: mechanism and functional targets.

Authors:  Chellappagounder Thangavel; Ettickan Boopathi; Adam Ertel; Meng Lim; Sankar Addya; Paolo Fortina; Agnieszka K Witkiewicz; Erik S Knudsen
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

Review 5.  MicroRNAs as diagnostic and prognostic biomarkers in colorectal cancer.

Authors:  Rui Yi; Yao Li; Fei-Liang Wang; Gang Miao; Ruo-Mei Qi; Yan-Yang Zhao
Journal:  World J Gastrointest Oncol       Date:  2016-04-15

Review 6.  MicroRNA-21 as a potential colon and rectal cancer biomarker.

Authors:  Tao Li; Mei Ha Leong; Bruce Harms; Gregory Kennedy; Lin Chen
Journal:  World J Gastroenterol       Date:  2013-09-14       Impact factor: 5.742

Review 7.  MicroRNAs in Pancreatic Cancer: Involvement in Carcinogenesis and Potential Use for Diagnosis and Prognosis.

Authors:  Tereza Halkova; Romana Cuperkova; Marek Minarik; Lucie Benesova
Journal:  Gastroenterol Res Pract       Date:  2015-04-19       Impact factor: 2.260

8.  Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab.

Authors:  Mogens K Boisen; Christian Dehlendorff; Dorte Linnemann; Boye S Nielsen; Jim S Larsen; Kell Osterlind; Svend E Nielsen; Line S Tarpgaard; Camilla Qvortrup; Per Pfeiffer; Niels H Holländer; Nina Keldsen; Torben F Hansen; Brita B Jensen; Estrid V S Høgdall; Benny V Jensen; Julia S Johansen
Journal:  PLoS One       Date:  2014-10-15       Impact factor: 3.240

9.  Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.

Authors:  Martin A Rivas; Leandro Venturutti; Yi-Wen Huang; Roxana Schillaci; Tim Hui-Ming Huang; Patricia V Elizalde
Journal:  Breast Cancer Res       Date:  2012-05-14       Impact factor: 6.466

10.  Reanalysis of the gene expression profile in chronic pancreatitis via bioinformatics methods.

Authors:  Hang Yuan; Bin Wu; Senlin Ma; Xiaoyu Yang; Lei Yin; Aijun Li
Journal:  Eur J Med Res       Date:  2014-05-29       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.